# Organon & Co. (OGN) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Biotechnology. Price $13.85, market value $3.6 billion.

## Valuation
- **P/E (trailing): 17.8×** (5-yr avg 5.8×, 3-yr avg 5.9×). Organon & Co. trades at 17.8× trailing earnings, well above its own five-year average of 5.8×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 3.8×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 0.6×**. Each dollar of revenue is priced at 0.6×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 3.0×**. The shares trade at 3.0× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 18.6%** (5-yr avg 21.4%). Free cash flow equals 18.6% of the market value, in line with its five-year average of 21.4%. Above 5% is generally attractive.
- **Earnings yield: 5.6%**. The inverse of the P/E: 5.6% of the price is earned each year.

## Profitability
- **Gross margin: 53.1%**. Organon & Co. keeps 53.1% of revenue after the direct cost of what it sells.
- **Net margin: 3.0%**. 3.0% of each dollar of sales reaches the bottom line.
- **Return on equity: 24.9%**. 24.9% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on assets: 1.7%**. Each dollar of assets produces 1.7% of profit.

## Growth
- **Revenue growth (1 yr): -2.9%** (3-yr 0.2%/yr, 5-yr -1.0%/yr). Revenue fell 2.9% over the last year, against -1.0% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -78.4%** (3-yr -41.5%/yr, 5-yr -39.0%/yr). Earnings per share fell 78.4%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -6.7%/yr**. Free cash flow has compounded at -6.7% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 11.49**. Debt is 11.49 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Current ratio: 1.82** (quick 1.82). Current assets cover the next year's liabilities 1.82 times.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.58%** ($0.08 per share, trailing). Organon & Co. yields 0.58%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 47%** (3% of free cash flow). 47% of earnings goes out as dividends, leaving room to keep raising it.

## Analyst view
- **Analyst consensus: hold** (3 analysts). 3 analysts cover Organon & Co.; the consensus is hold, with an average price target of $10.33 (-25% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 106.1%** (YTD 93.5%, 3-mo 1.9%). The shares are up 106.1% over twelve months including dividends.
- **From 52-week high: 0.0%** (143.4% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 63**. An RSI of 63 is neutral.
- **Beta (1 yr): 0.61** (volatility 60%). Beta of 0.61 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=OGN · Page: https://foliofundamentals.com/stocks/ogn

Not investment advice.